

BJ



(19)

Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 1 213 017 A2

(12)

## EUROPEAN PATENT APPLICATION

(43) Date of publication:  
12.06.2002 Bulletin 2002/24

(51) Int Cl.<sup>7</sup>: A61K 31/00, A61K 31/496,  
A61K 31/40, A61P 15/12

(21) Application number: 01204601.7

(22) Date of filing: 29.11.2001

(84) Designated Contracting States:  
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE TR  
Designated Extension States:  
AL LT LV MK RO SI

(30) Priority: 05.12.2000 EP 00204378

(71) Applicant: Akzo Nobel N.V.  
6824 BM Arnhem (NL)

(72) Inventor: Berendsen, Hermanus Henricus  
Gerardus  
5340 BH Oss (NL)

(74) Representative: Kraak, Hajo et al  
Patent Department Pharma  
N.V. Organon,  
Postbus 20  
5340 BH Oss (NL)

### (54) Use of a 5-HT<sub>2C</sub> receptor agonist for the treatment of hot flushes

(57) The present invention relates to a method of treatment of hot flushes with a 5-HT<sub>2C</sub> receptor agonist and in particular to the use of the selective 5-HT<sub>2C</sub> receptor agonists 1-[6-chloro-5-(trifluoromethyl)-2-pyridinyl]-piperazine and (S)-(+)-3-[(2,3-dihydro-5-methoxy-

1H-inden-4-yl)oxypyrrolidine or pharmaceutically acceptable acid addition salts thereof for the manufacture of a pharmaceutical formulation adapted for the treatment of hot flushes.

EP 1 213 017 A2

**Description**

[0001] The invention relates to the use of a serotonergic compound for the treatment of hot flushes.

[0002] The most well-known complaints of the (post)-menopausal syndrome are due to changes in temperature regulation, causing sudden crises of feelings of excessive body heat (hot flushes). These symptoms are highly disturbing for a large proportion of menopausal women, leading to therapy requests to the medical profession. Usually, replacement of estrogens is selected as remedy. Less commonly and more recently explored is the selection of non-hormonal compounds as medicine for treating hot flushes. For example, the use of serotonergic uptake inhibitors and serotonin (= 5-hydroxy-tryptophan = 5-HT) antagonists for the treatment of hot flushes is discussed in Berendsen, Maturitas Vol 36, pp 155-164, 2000. Some beneficial effects of 5-HT<sub>2A</sub> antagonists and serotonin uptake inhibitors were reported. The beneficial effect of the serotonin reuptake inhibitors sertraline and paroxetine were described in Plouffe et al., Delaware Medical Journal 69: pp 481-482, 1997, Roth and Scher, Psycho-Oncology 7, pp 129-132, 1998, and Stearns et al., Annals of Oncology 11, pp 17-22, 2000.

[0003] It has now been found that an agonist for 5-HT<sub>2C</sub> receptors in an organism can be used for a method of treatment of hot flushes.

[0004] Unexpectedly, these 5-HT<sub>2C</sub>-agonists produce better results than SSRI's against hot flushes in view of the extent to which side effects are compensated for by efficacy.

[0005] Thus, the invention provides for a method of treatment of hot flushes with a 5-HT<sub>2C</sub> receptor agonist. In particular, a selective 5-HT<sub>2C</sub> receptor agonist is preferred. A selective 5-HT<sub>2C</sub> receptor agonist in the context of the description of this invention means a 5-HT<sub>2C</sub> receptor agonist which is more active as agonist on 5-HT<sub>2C</sub> receptors than on other 5-HT receptor subtypes, such as 5-HT<sub>1A</sub>, 5-HT<sub>2A</sub> and/or 5-HT<sub>3</sub> receptors. The selective 5-HT<sub>2C</sub> receptor agonist should preferably be such that it is at least 5 times more active on 5-HT<sub>2C</sub> receptors than on the other serotonin receptors. The 5-HT agonists described in EP 370 560 are particularly suitable for the use of this invention. Specifically 1-[6-chloro-5-(trifluoromethyl)-2-pyridinyl]-piperazine and its pharmaceutically acceptable acid addition salts have the most desirable properties out of this group for the use of this invention. More preferred is the use of a 5-HT<sub>2C</sub> agonist being at least 10 times more active on 5-HT<sub>2C</sub> receptors relative to 5-HT<sub>2A</sub> receptors. Most preferred is the use of the azetidines or pyrrolidine compounds disclosed in EP863136 for use in the treatment of hot flushes, and in particular the compound (S)-(+)-3-[(2,3-dihydro-5-methoxy-1H-inden-4-yl)oxy]pyrrolidine or its pharmaceutically acceptable acid addition salts described in that disclosure.

[0006] Since the treatment of the present invention is not based on hormone replacement these treatment agents are preferably used in those circumstances where treatment with a hormone or a hormone receptor agonist bears higher risks. Therefore, an aspect of this invention is that it makes a treatment available for hot flushes in patients at risk for hormone dependent tumour growth. Such patients are the group of patients with ovariectomy in view of estrogen dependent tumour growth.

[0007] Another aspect of the invention is that it makes a treatment available for hot flushes in patients with adverse feminizing responses to estrogens. In particular, male patients functionally or pharmacologically castrated for the purpose of removing endogenous hormones can be treated for hot flushes with 5-HT<sub>2C</sub>-agonists. Hot flushes not only occur as complaint during menopause, but also in certain women during specific points in time of the menstrual cycle, for example before and during the days of menstruation. It is an aspect of this invention that hot flushes in those circumstances can be very well non-hormonally treated with a 5-HT<sub>2C</sub> agonist.

[0008] Determination of selectivity of a receptor agonist can be done by methods well known in the art. The basic technique is with binding experiments in which the compound is tested for binding affinity to the subtypes of receptors. Alternatively, selectivity can be determined with in vitro expression systems in which a biochemical parameter, such as cyclic adenosine monophosphate or phosphoinositol production or inhibition is used to determine receptor activation by an agonist. In vivo methods can also be used when selective models for testing receptor stimulation are available. Some differences in the selectivity results obtained with these methods can occur. Usually, and under the condition that the test is accepted as reliable, the in vivo selectivity is the preferred indicator for determination of selectivity of a compound over in vitro methods. Results with in vitro expression of receptor activity are in turn more preferred for determination of the selectivity than binding experiments. For a suitable collection of techniques to determine the prop-

erties of a 5-HT<sub>2C</sub> agonist reference is made to Martin et al., 5-HT<sub>2C</sub> receptor agonists: Pharmacological characteristics and therapeutic potential. *J. Pharmacol & Experimental Therapeutics* 286: 913-924, 1998

[0009] The present invention further includes the use of a 5-HT<sub>2C</sub>-agonist for the manufacture of a medicament for the treatment of hot flushes.

5 [0010] Suitable acid addition salts include hydrochloric, fumaric, maleic, citric or succinic acid, these acids being mentioned only by way of illustration and without implied limitation. A preferred salt is the hydrochloric acid salt.

[0011] The amount of a 5-HT<sub>2C</sub> agonist, also referred to herein as the active ingredient, which is required to achieve a therapeutic effect will, of course, vary with the particular compound, the route of administration and the age and other conditions of the recipient.

10 [0012] A suitable daily dose for any of the two compounds chemically named above will be in the range of 5 to 140 mg of the base per person per day, preferably in the range of 20 to 70 mg of the base per recipient per day. In the case of tolerance development, treatments can be further optimised by increasing the dose up to 5 times in the course of a chronic treatment in humans. The desired dose may be presented as one, two, three or more sub-doses administered at appropriate intervals throughout the day.

15 [0013] While it is possible for the active ingredient to be administered alone, it is preferable to present it as a pharmaceutical formulation. Accordingly, the present invention further provides a pharmaceutical formulation for use in the treatment of hot flushes comprising a 5-HT<sub>2C</sub>-agonist, together with a pharmaceutically acceptable carrier thereof and optionally other therapeutic agents. The carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipients thereof. The invention further includes a pharmaceutical formulation, as hereinbefore described, in combination with packaging material suitable for the pharmaceutical formulation, said packaging material including instructions for the use of the pharmaceutical formulation in the treatment of hot flush.

20 [0014] Formulations include those suitable for oral, rectal, nasal, topical (including transdermal, buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous, intradermal and epidural) administration. The formulations may be prepared by any methods well known in the art of pharmacy, for example, using methods such as those described in Gennaro et al., Remington's Pharmaceutical Sciences ( 18th ed., Mack Publishing company, 1990, see especially Part 8 : Pharmaceutical Preparations and their Manufacture). Such methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients. Such accessory ingredients include those conventional in the art, such as, fillers, binders, diluents, disintegrants, lubricants, colorants, flavoring agents and wetting agents.

25 [0015] Formulations suitable for oral administration may be presented as discrete units such as tablets or capsules each containing a predetermined amount of active ingredient; as a powder or granulates; as a solution or suspension. The active ingredient may also be presented as a bolus or paste, or may be contained within liposomes or microparticles.

30 [0016] Formulations for rectal administration may be presented as a suppository or enema.

[0017] For parenteral administration, suitable formulations include aqueous and non-aqueous sterile injection. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed vials and ampoules, and may be stored in a freeze dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example, water prior to use.

40 [0018] Formulations suitable for administration by nasal inhalation include fine dusts or mists which may be generated by means of metered dose pressurised aerosols, nebulisers or insufflators.

[0019] Formulations may, for example, be presented in a suitable sustained release form, for example, in a device such as the Minipump™.

[0020] The compounds according to the present invention are non-toxic.

45 [0021] The the compounds 1-[6-chloro-5-(trifluoromethyl)-2-pyridinyl]-piperazine and (S)-(+)-3-[(2,3-dihydro-5-methoxy-1H-inden-4-yl)oxy]pyrrolidine, and their pharmaceutically acceptable acid addition salts may be prepared by any method known in the art for the preparation of a compound of similar structure. Typically the compound 1-[6-chloro-5-(trifluoromethyl)-2-pyridinyl]-piperazine can be prepared by the methods described in EP 370 560, the contents of which are incorporated herein by reference, whereas the compound (S)-(+)-3-[(2,3-dihydro-5-methoxy-1H-inden-4-yl)oxypyrrrolidine and its pharmaceutically acceptable acid addition salts can be prepared by the methods described in EP863136, the contents of which are incorporated herein by reference.

50 [0022] The following example is for illustration and should not be considered to be limiting in anyway:-

#### Example

55

[0023] A test for demonstration of the effect of compounds on an acute increment of body heat production representative for hot flushes in humans is based on telemetric body temperature measurements in freely moving rats.

Method

[0024] Male rats (HSD/Cpb:WU, Harlan Sprague Dawley, Zeist, The Netherlands), weighing 350-480 g, were used.

5 The rats were implanted with a Physio Tel TA11CTA-F40 Implant (Data Sciences International) under pentobarbital anaesthesia. After surgery the rats were housed individually in a type II clear Macrolon™ cage (23x17xx14 cm). The cages were placed on receivers (RLA 1020). After a recovery and adaptation period of at least one week the rats were used for the experiments. On the experimental day, body temperature, heart rate and locomotor activity was monitored for 30 minutes prior to injection of vehicle or test compound. This period provides a baseline core body temperature relative to which the changes of body temperature after the manipulation of the rats for injection are expressed. After 10 30 minutes the rats were injected subcutaneously with vehicle or test compound and the same parameters were measured for at least 60 minutes. Immediately after injection the core body temperature rises. Compounds inhibiting this rise in temperature reveal an inhibiting effect on acute body heat production. Results obtained with other parameters, such as the effect on heart rate and on locomotor activity are not presented here. 6 animals were used for measurement of each dose of compound

15 Compounds tested are:

1-[6-chloro-5-(trifluoromethyl)-2-pyridinyl]-piperazine HCl, which is indicated as Org 12962.

(S)-(+)-3-[(2,3-dihydro-5-methoxy-1H-inden-4-yl)oxy]pyrrolidine HCl, which is indicated as Org 37684.

Fluoxetine HCl

20

[0025] Data were analysed using Dataquest IV Data Acquisition System Ver 2.2. Compounds were dissolved in NaCl 0.9 % (m/v) in water as vehicle for subcutaneous injection.

Table 1

Effect of Org 37684 on temperature increments after manipulation of the rats relative to the body temperature during 30 minutes prior to the manipulation.				
	Org 37684	Org 37684	Org 37684	Org 37684
<b>Dose:</b>	0 mg/kg	1.0 mg/kg	2.2 mg/kg	4.6 mg/kg
<b>Time<sup>1</sup></b>				
5	0.50 <sup>2</sup>	0.29	0.41	0.00
10	0.69	0.68	0.47	-0.03
15	0.79	0.78	0.44	-0.13
20	0.80	0.58	0.40	-0.20
25	0.81	0.69	0.24	-0.14
30	0.60	0.63	0.13	-0.24
35	0.40	0.49	0.04	-0.24
40	0.41	0.40	-0.05	-0.27
45	0.30	0.20	-0.09	-0.34
50	0.27	0.14	-0.21	-0.40
55	0.24	0.34	-0.26	-0.43
60	0.20	0.14	-0.25	-0.33

<sup>1</sup> is time after injection in minutes

50 <sup>2</sup> numbers in the tables represent absolute mean increments in body temperature in °C for 6 rats relative to baseline during 30 minutes prior to manipulation of the animals.

Table 2.

Effect of Org 12962; explanation as for table 1		
	Org 12962	Org 12962
5	Dose:	0 mg/kg
10	Time	
15	5	0.90
20	10	1.06
25	15	1.03
30	20	0.92
35	25	0.93
40	30	0.83
45	35	0.81
50	40	0.72
55	45	0.66
60	50	0.65
	55	0.51
	60	0.41
		-0.16

Table 3.

Effect of fluoxetine; explanation as for table 1		
	Fluoxetine	Fluoxetine
30	Dose:	0 mg/kg
35	Time	
40	5	0.72
45	10	0.96
50	15	0.97
	20	0.90
	25	0.89
	30	0.80
	35	0.69
	40	0.65
	45	0.53
	50	0.41
	55	0.33
	60	0.18
		0.85

Interpretation of results:

55 [0026] The rise in body temperature of up to slightly less than 1 °C within the period of 60 minutes after manipulation for injecting the animals was prevented by Org 12962 or by Org 37684, but not by fluoxetine. The prevention of temperature rise was statistically significant for the two 5-HT<sub>2C</sub> agonists with the ANOVA/MANOVA Tukey HSD test on sample points. The results are interpreted to indicate that 5-HT<sub>2C</sub> agonists counteract acute increments in body tem-

perature such as those which occur during a hot flush.

**Claims**

5

1. A method of treatment of hot flushes, **characterised in that** the treatment is with a 5-HT<sub>2C</sub> receptor agonist.
2. A use of a 5-HT<sub>2C</sub>-agonist for the manufacture of a medicament, **characterised in that** the medicament is for the treatment of hot flushes.
- 10 3. The method or use according to claim 1 or 2 respectively, **characterised in that** the 5-HT<sub>2C</sub> receptor agonist is a selective 5-HT<sub>2C</sub> receptor agonist.
- 15 4. The method or use according to claim 3, **characterised in that** the selective 5-HT<sub>2C</sub> receptor agonist is selective to an extent that the 5-HT<sub>2C</sub> receptor agonist is at least 5 times more active on 5-HT<sub>2C</sub> receptors than on other serotonin receptors.
- 20 5. The method or use according to claim 3, **characterised in that** the selective 5-HT<sub>2C</sub> receptor agonist is selective to an extent that it is at least 10 times more active on 5-HT<sub>2C</sub> receptors than on 5-HT<sub>2A</sub> receptors.
- 25 6. The method or use according to claim 3, **characterised in that** the selective 5-HT<sub>2C</sub> receptor agonist is 1-[6-chloro-5-(trifluoromethyl)-2-pyridinyl]-piperazine or (S)-(+)-3-[(2,3-dihydro-5-methoxy-1H-inden-4-yl)oxy]pyrrolidine or a pharmaceutically acceptable acid addition salt thereof.
7. A pharmaceutical formulation adapted for the treatment of hot flushes comprising 1-[6-chloro-5-(trifluoromethyl)-2-pyridinyl]-piperazine or (S)-(+)-3-[(2,3-dihydro-5-methoxy-1H-inden-4-yl)oxy]pyrrolidine or a pharmaceutically acceptable acid addition salt thereof, together with a pharmaceutically acceptable carrier therefor.

30

35

40

45

50

55



(19)

Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11)

EP 1 213 017 A3

(12)

EUROPEAN PATENT APPLICATION

(88) Date of publication A3:  
12.11.2003 Bulletin 2003/46

(51) Int Cl.<sup>7</sup>: A61K 31/00, A61K 31/496,  
A61K 31/40, A61P 15/12

(43) Date of publication A2:  
12.06.2002 Bulletin 2002/24

(21) Application number: 01204601.7

(22) Date of filing: 29.11.2001

(84) Designated Contracting States:  
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE TR

Designated Extension States:  
AL LT LV MK RO SI

(30) Priority: 05.12.2000 EP 00204378

(71) Applicant: Akzo Nobel N.V.  
6824 BM Arnhem (NL)

(72) Inventor: Berendsen, Hermanus Henricus  
Gerardus  
5340 BH Oss (NL)

(74) Representative: Kraak, Hajo et al  
Patent Department Pharma  
N.V. Organon,  
Postbus 20  
5340 BH Oss (NL)

(54) Use of a 5-HT<sub>2C</sub> receptor agonist for the treatment of hot flushes

(57) The present invention relates to a method of treatment of hot flushes with a 5-HT<sub>2C</sub> receptor agonist and in particular to the use of the selective 5-HT<sub>2C</sub> receptor agonists 1-[6-chloro-5-(trifluoromethyl)-2-pyridinyl]-piperazine and (S)-(+)-3-[(2,3-dihydro-5-methoxy-

1*H*-inden-4-yl)oxypyrrolidine or pharmaceutically acceptable acid addition salts thereof for the manufacture of a pharmaceutical formulation adapted for the treatment of hot flushes.

EP 1 213 017 A3



European Patent  
Office

## PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention  
shall be considered, for the purposes of subsequent  
proceedings, as the European search report

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
P, X	NL 1 014 289 C (WALDINGER MARCEL DAVID DR ; SCHWEITZER DAVE HENRY DR (NL)) 7 August 2001 (2001-08-07) * the whole document * ----	1-5	A61K31/00 A61K31/496 A61K31/40 A61P15/12
D, X	BERENDSEN H H: "The role of serotonin in hot flushes." MATERITAS, (2000 OCT 31) 36 (3) 155-64. REF: 95, XP000997935 * abstract * * page 159 - page 160 * ----	1-5, 7	
Y		6	
X	EP 0 943 329 A (LILLY CO ELI) 22 September 1999 (1999-09-22) * the whole document * ----	1-5, 7	
X	CL. LOPRINZI ET AL.: "PRELIMINARY DATA FROM A RANDOMIZED EVALUATION OF FLUOXETINE (PROZAC) FOR TREATING HOT FLASHES IN BREAST CANCER SURVIVORS" BREAST CANCER RESEARCH AND TREATMENT, vol. 57, 1999, page 34 XP000997939 * abstract * ----	1-5, 7	
		-/-	
<b>INCOMPLETE SEARCH</b>			
<p>The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.</p> <p>Claims searched completely:</p> <p>Claims searched incompletely:</p> <p>Claims not searched:</p> <p>Reason for the limitation of the search:</p> <p>see sheet C</p>			
Place of search		Date of completion of the search	
THE HAGUE		19 September 2003	
Examiner		Hoff, P	
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			
T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons ..... & : member of the same patent family, corresponding document			



Although claims 1,3-6 are directed to a method of treatment of the human/animal body (Article 52(4) EPC), the search has been carried out and based on the alleged effects of the compound/composition.

Claim(s) searched completely:  
6,7

Claim(s) searched incompletely:  
1-5

Reason for the limitation of the search:

Present claims 1-5 relate to a compound defined by reference to a desirable characteristic or property, namely "5-HT2C receptor agonist".

The claims cover all compounds having this characteristic or property, whereas the application provides support within the meaning of Article 84 EPC and disclosure within the meaning of Article 83 EPC for only a very limited number of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 84 EPC). An attempt is made to define the compound by reference to its pharmacological profile. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible.

Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the compounds structurally identified in claims 6 and 7, with due regard to the general idea underlying the present invention.



European Patent  
Office

## PARTIAL EUROPEAN SEARCH REPORT

Application Number  
EP 01 20 4601

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
A	P.J. GOODNICK ET AL.: "SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN AFFECTIVE DISORDERS-I. BASIC PHARMACOLOGY" JOURNAL OF PSYCHOPHARMACOLOGY, vol. 12, no. 3, 1998, pages S5-S20, XP000997895 * abstract * * page S8, right-hand column, paragraph 2 * ---	1-5,7	
D,X	EP 0 863 136 A (AKZO NOBEL NV) 9 September 1998 (1998-09-09) * abstract * * page 2, line 1 - page 3, line 6; claims; 6 example 9 *	7	
Y	JENCK, FRANCOIS ET AL: "Antiaversive effects of 5HT2C receptor agonists and fluoxetine in a model of panic-like anxiety in rats" EUR. NEUROPSYCHOPHARMACOL. (1998), 8(3), 161-168, XP000997971 * the whole document *	6	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
D,X	EP 0 370 560 A (AKZO NV) 30 May 1990 (1990-05-30) * the whole document *	7	
		-/--	



European Patent  
Office

## PARTIAL EUROPEAN SEARCH REPORT

Application Number

EP 01 20 4601

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
D,A	<p>E A TROTT ET AL: "an open trial of sertraline for menopausal hot flushes: potential involvement of serotonin in vasomotor instability" DELAWARE MEDICAL JOURNAL, US, WILMINGTON, DE, vol. 9, no. 69, 1997, pages 481-482, XP002078238 ISSN: 0011-7781 * the whole document *</p> <p>-----</p>	1-7	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)

ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.

EP 01 20 4601

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

19-09-2003

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
NL 1014289	C	07-08-2001	NL	1014289 C1	07-08-2001
EP 0943329	A	22-09-1999	AU	3306399 A	20-09-1999
			BR	9908431 A	31-10-2000
			CA	2321648 A1	10-09-1999
			CN	1291889 T	18-04-2001
			EP	0943329 A1	22-09-1999
			HU	0101404 A2	28-10-2001
			JP	2002505280 T	19-02-2002
			NO	20004331 A	31-08-2000
			PL	342883 A1	16-07-2001
			SK	12982000 A3	09-04-2001
			TR	200002507 T2	21-12-2000
			WO	9944601 A1	10-09-1999
EP 0863136	A	09-09-1998	WO	9943647 A1	02-09-1999
			EP	0863136 A1	09-09-1998
			AU	754745 B2	21-11-2002
			AU	6500298 A	15-09-1999
			BR	9815690 A	24-10-2000
			CA	2321188 A1	02-09-1999
			JP	2002512940 T	08-05-2002
			NZ	506465 A	29-08-2003
			RU	2198873 C2	20-02-2003
			TR	200002466 T2	21-12-2000
			US	6281243 B1	28-08-2001
			US	2002040016 A1	04-04-2002
EP 0370560	A	30-05-1990	AT	100087 T	15-01-1994
			AU	621419 B2	12-03-1992
			AU	4538789 A	31-05-1990
			CA	2003665 A1	24-05-1990
			DE	68912282 D1	24-02-1994
			DE	68912282 T2	28-04-1994
			DK	587989 A	25-05-1990
			EP	0370560 A1	30-05-1990
			ES	2061953 T3	16-12-1994
			IE	62792 B1	08-03-1995
			JP	2184672 A	19-07-1990
			JP	2873025 B2	24-03-1999
			KR	155543 B1	16-11-1998
			NZ	231487 A	29-01-1991
			US	4971969 A	20-11-1990
			ZA	8908728 A	29-08-1990